pd 153035 has been researched along with Benign Neoplasms in 8 studies
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline: structure given in first source
PD-153035 : A member of the class of quinazolines carrying a 3-bromophenylamino substituent at position 4 and two methoxy substituents at positions 6 and 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A number of anticancer drugs with 4-aminoquinazoline core are in the market, e." | 2.61 | Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry. ( Das, D; Hong, J, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gangjee, A | 1 |
| Zaware, N | 1 |
| Raghavan, S | 1 |
| Yang, J | 1 |
| Thorpe, JE | 1 |
| Ihnat, MA | 1 |
| Li, Y | 1 |
| Xiao, J | 1 |
| Zhang, Q | 1 |
| Yu, W | 1 |
| Liu, M | 1 |
| Guo, Y | 1 |
| He, J | 1 |
| Liu, Y | 1 |
| Das, D | 1 |
| Hong, J | 1 |
| Sakanyan, V | 1 |
| Angelini, M | 1 |
| Le Béchec, M | 1 |
| Lecocq, MF | 1 |
| Benaiteau, F | 1 |
| Rousseau, B | 1 |
| Gyulkhandanyan, A | 1 |
| Gyulkhandanyan, L | 1 |
| Logé, C | 1 |
| Reiter, E | 1 |
| Roussakis, C | 1 |
| Fleury, F | 1 |
| Hirata, M | 1 |
| Kanai, Y | 1 |
| Naka, S | 1 |
| Matsumuro, K | 1 |
| Kagawa, S | 1 |
| Yoshimoto, M | 1 |
| Ohmomo, Y | 1 |
| Kohno, M | 1 |
| Horibe, T | 1 |
| Haramoto, M | 1 |
| Yano, Y | 1 |
| Ohara, K | 1 |
| Nakajima, O | 1 |
| Matsuzaki, K | 1 |
| Kawakami, K | 1 |
| Fredriksson, A | 1 |
| Stone-Elander, S | 1 |
| Kunkel, MW | 1 |
| Hook, KE | 1 |
| Howard, CT | 1 |
| Przybranowski, S | 1 |
| Roberts, BJ | 1 |
| Elliott, WL | 1 |
| Leopold, WR | 1 |
3 reviews available for pd 153035 and Benign Neoplasms
| Article | Year |
|---|---|
The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Humans; Neoplasms; Protein Kinase Inhibitors; Pr | 2019 |
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
Topics: Animals; Antineoplastic Agents; Chemistry Techniques, Synthetic; Humans; Neoplasms; Protein Kinase I | 2019 |
PET screening of anticancer drugs. A faster route to drug/target evaluations in vivo.
Topics: Animals; Antineoplastic Agents; Drug Evaluation; Drug Screening Assays, Antitumor; Enzyme Inhibitors | 2003 |
5 other studies available for pd 153035 and Benign Neoplasms
| Article | Year |
|---|---|
N⁴-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation.
Topics: Animals; Binding Sites; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; | 2012 |
Screening and discovery of nitro-benzoxadiazole compounds activating epidermal growth factor receptor (EGFR) in cancer cells.
Topics: Cell Line, Tumor; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Humans; Neoplasms; Nitro Com | 2014 |
Evaluation of radioiodinated quinazoline derivative as a new ligand for EGF receptor tyrosine kinase activity using SPECT.
Topics: Animals; Cell Line, Tumor; ErbB Receptors; Humans; Iodine Radioisotopes; Ligands; Male; Mice; Neopla | 2011 |
A novel hybrid peptide targeting EGFR-expressing cancers.
Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; | 2011 |
Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice.
Topics: Animals; Carcinoma, Squamous Cell; Cell Division; Enzyme Inhibitors; ErbB Receptors; Humans; Mice; M | 1996 |